Articles On Eve Investments (ASX:EVE)

EVE Health Group (ASX: EVE) has entered into a telehealth services agreement with hubMed to enhance the quality and continuity of care for patients using EVE’s therapeutic products including Dyspro for dysmenorrhoea and Libbo for erectile d...

EVE Health Group (ASX: EVE) has appointed its first dedicated medical science liaison (MSL) to lead national medical education and prescriber engagement programs across Australia.

EVE Health Group (ASX: EVE) has reached several key milestones in its transition to commercial operations, achieving first patient prescriptions of its Dyspro cannabinoid-based gummy and submitting the initial purchase order for Libbo, an o...

EVE Health Group (ASX: EVE) has received stong support from sophisticated and professional investors for a capital raising aimed at accelerating the commercial rollout of its lead pharmaceutical products Dyspro and Libbo. When the placement...

ASX slides 24.6 points with 10 of 11 sectors lower Materials sector squeaks into green on gold gains Resources stocks limit broad losses Gold miners do the hard yards The ASX 200 moved broadly lower today, down 0.27% on general market we...

EVE Health Group (ASX: EVE) has prescribed its Dyspro cannabinoid-based gummy for the treatment of dysmenorrhoea and endometriosis to Australian patients for the first time. EVE issued the drug under the Therapeutic Goods Administration’s S...

EVE Health Group (ASX: EVE) has commenced dispatching its proprietary women’s health product Dyspro to distribution partners in preparation for an Australian launch. Dyspro is a first-in-class, cannabinoid-based gummy for the symptoms of dy...

EVE Health Group (ASX: EVE) has appointed senior research scientist Dr Fiona Cousins as the inaugural member of its new scientific advisory board. Dr Cousins has more than a decade of experience in reproductive biology and women’s health re...

EVE Health Group (ASX: EVE) has submitted its first commercial purchase order for Libbo, the company’s proprietary oral dissolving film treatment for erectile dysfunction (ED). One of the company’s GMP-certified pharmaceutical partners rece...

EVE Health Group (ASX: EVE) has posted a transformational quarter of activity, underpinned by the $3 million acquisition of biotech company Nextract. The purchase was settled through the issue of 83.33 million fully paid EVE shares at a pos...

EVE Health Group (ASX: EVE) has satisfied the regulatory requirements to enable Australian doctors to have prescription access to lead products Libbo (for erectile dyfunction) and Dyspro (for dysmenorrhoea). The approval falls under the The...

EVE Health Group (ASX: EVE) has submitted the first commercial purchase order for its proprietary gummy-format pharmaceutical product Dyspro to support women experiencing dysmenorrhoea (painful menstruation) and related health concerns. Dys...

EVE Health Group’s (ASX: EVE) wholly-owned subsidiary Nextract has signed an agreement with TeleDocs Clinic & Consulting for the online prescription and promotion of its lead pharmaceutical products for erectile dysfunction (ED) and dys...

EVE Health Group (ASX: EVE) has completed its strategic acquisition of biotech company Nextract in a major product growth move by the company. The successful purchase adds significant development upside in the $8.1 billion erectile dysfunct...

EVE Health Group (ASX: EVE) has commenced stability testing of its leading oral formulation products for treating erectile dysfunction (ED) and dysmenorrhoea (period pain). Stability testing is mandatory under pharmaceutical product researc...

Highlights ASX 200 set for a softer open after a choppy Wall Street session US trade tensions resurface as courts debate tariff rulings Key Australian retail data expected to influence domestic sentiment The Australian...

Energy sector pushes ASX 0.15pc higher US court has ruled Trump’s Liberation Day and fentanyl tariffs are unlawful Steel, aluminium and auto tariffs remain in place   The ASX has posted another gain today, albeit a small 0.15% lift. News...

EVE Health (ASX: EVE) will execute a change in direction from functional foods to regulated health markets with a $3 million acquisition of biotech company Nextract and its oral delivery technologies. Nextract’s lead product is an alcohol-f...

EVE Health Group (ASX: EVE) has launched a $3 million takeover bid for Australian biotech company Nextract as part of a strategic move to transition from a natural wellness brand into a broader health platform targeting regulated markets. H...

A momentum trader will essentially be “buying high, but hoping to sell even higher” – which is the counter to the well known strategy of “buy low and sell high”. The biggest question for momentum traders is therefore how to find those stock...

EVE Health Group (EVE) has entered a trading halt after announcing its intention to raise fresh capital The health and wellness company ended the December quarter with $941,000 in cash and one quarter left of funding and said it was assess...

After the Russia-Ukraine crisis sent US investors back into their shell overnight, ASX investors were comparatively sanguine in Friday trade. Large caps still finished in the red, but a host of gains among junior explorers saw the microcap...

EVE Health Group (EVE) provides an unaudited half yearly update for its subsidiary, Meluka Australia, reporting an increase in revenue of 34 per cent to $750,000 It reports Australian revenue is up 359 per cent, US revenue is up 21 per cen...

After trading down for most of the day, the ASX ultimately closed higher despite a big sell off in tech. The ASX 200 closed at 7,245 points which was 0.05% higher than Friday. Tech retreated 2.2% over inflation fears but gains of over 1.9%...

US stocks tumbled on Friday All three major US stock markets tumbled on Friday, as mega tech stocks fell hard. The Nasdaq was down by 1.92%, the S&P500 by 0.85%, and the Dow Jones index by 0.17%. Weak non-farm payrolls added to the unce...

Just like yesterday the ASX rallied for most of the day but retreated in the afternoon and today closed in the red. The ASX 200 was down 0.08% at 7,375 points. Another difference from yesterday was tech was the best sector gaining 1.7% whil...

Of all the ASX stocks releasing quarterlies or general financial updates this morning, honey and honey-based product exporter Eve Investments (ASX:EVE) impressed the most.   EVE Investments (ASX:EVE) This microcap stock rose as much as 60%...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The Community College of Denver (CCD) has just launched a cannabis business program in Colorado. The new program offers students the opportunity to earn an Associate of Applied Science degree designed to prepare them to become business mana...

On the Bid is a new Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this edition, host Oriel Morrison discusses the rapidly growing potash market. Populating the expert panel this wee...

Summary GBR share price has skyrocketed by a massive 91.3% to AU$0.088. Eve Investments’ confirmed first purchase order has led its share price to rise by 16.67% to AU$0.007. BOE’s share price opened with a gap and surpassed its 52-we...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Eve Investments (ASX:EVE) has confirmed its roll out into American multinational supermarket chain Whole Foods with two products to be ranged in all 48 stores in Whole Foods’ North Western California network. The products will launch in sto...

The number of medical cannabis prescriptions issued under Australia’s special access scheme just keeps on growing. There were a record 9,959 SAS Category B marijuana prescriptions issued in March, two and a half times the number from a year...

Special Report: Eve Investments reports record sales in USA, Australia in its December 2020 Quarterly Update. ... Read More The post Eve Investments reports record quarter boosted by Amazon online sales appeared first on Stockhead.

Special Report: Omni Innovation, an Australian company specialising in medical nutrition, 38% owned by Eve Investments, has entered a licencing ... Read More The post Omni Innovation gets green light for multi-country distribution deal appe...

Special Report: Meluka Australia has chalked up another major milestone by selling out its entire second shipment of honey to China before it could be delivered. Australian owned and operated health and wellness company Meluka Australia, a...

Fiji Kava (ASX:FIJ) and EVE Investments (ASX:EVE) both surged in morning trade after revealing more money would be coming their way. Organic honey producer EVE updated shareholders on its China sales, saying that the latest shipment had bee...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

For the many companies in Australia’s medicinal cannabis sector, the health benefits of cannabidiol (CBD) products are self-evident. But a trial underway in the UK is also testing the safety and efficiency of cannabis-derived medicines to t...

By Tim Boreham, Editor, The New Criterion Organic growth: the next generation of stocks tapping the “wellness” boom Usually referred to in the same breath as health, “wellness” is an amorphous term but that hasn’t stopped investors from flo...

StockTalk is a new Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this edition, host Dr Nigel Finch discusses China’s rebounding economy and the companies, sectors and industries bes...

Special Report: ASX-listed health, nutrition and wellness company, EVE Investments, has launched its probiotic bio-fermented honey drink in Australia as the US and Japan wait in the wings. Capitalising on a groundswell for diversified healt...

Promising green shoots are appearing amid tumbling stocks as China reaches out to Australian producers amid the coronavirus outbreak.  While it’s doom and gloom in Australia’s retail sector, it’s a different story in some of the smaller sto...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Bill Fry, managing director of Eve Inv...

Special Report: ASX-listed health and wellness company, EVE Investments, has secured its first purchase orders in China for over 21,000 units of Meluka Honey as the company unveils a new product range and announces further plans for growth....

Special Report: Fresh off the back of securing a $9.3 million strategic placement, diversified health and wellness investment group EVE Investments is scaling up its commercialisation in the Asia Pacific region with a strategic expansion in...

Each week our Weed Week column wraps the news driving ASX cannabis stocks. Angela Merkel’s ruling conservative Christian Democratic Union (CDU) party might be contemplating a move to legalise cannabis in Germany, DW reported last week. “Can...

It’s been another interesting week in the realm of Australian cannabis regulation. For starters, the ACT legislature’s recent decision to legalise marijuana possession (up to a maximum of 50 grams) continued to grab some headlines. Senior m...

On Stockhead today: our report on the 100 best performing stocks for the year, how four directors put in $5.1 million to make a quick $1.4 million, what are the hottest stocks on the ASX right now and Dr Boreham’s prognosis of Suda. But fir...